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Background/Aims: Clevudine, a pyrimidine nucleoside analogue, has potent antiviral effects in patients with
chronic viral hepatitis B (CHB). We report the efficacy of initial treatment with clevudine in naïve patients with CHB
living in Daejeon and Chungcheong Province, South Korea. 
Methods: One hundred five adults with CHB were administered 30 mg of clevudine per day for an average of 51
weeks. We evaluated viral markers and liver biochemistry retrospectively every 3 months. 
Results: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and hepatitis B virus (HBV) DNA
before the treatment were 184 ± 188 IU/L, 150 ± 138 IU/L, and 7.1 ± 1.2 log copies/mL, respectively. Undetectable
rates (< 60 IU/mL) of DNA were 36.2%, 68.9%, 83.6%, 76.2%, and 75.8% at 12, 24, 36, 48, and 60 weeks,
respectively. Seroconversion rates were 9.1%, 13.6%, 24.6%, 26.5%, and 26.1% and ALT normalization rates
were 64.5%, 78.1%, 87.9%, 90.0% at 12, 24, 36, and 48 weeks, respectively. Six patients (5.7%) had a viral
breakthrough.
Conclusions: Clevudine is a useful drug in the initial treatment of patients with CHB, with a potent antiviral effect
and low incidence of viral breakthrough. (Korean J Intern Med 2010;25:372-376)
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INTRODUCTION
Hepatitis B virus (HBV) infection, which leads to
chronic hepatitis and cirrhosis, may be responsible for
life-threatening liver disease in some individuals, with 350
million carriers worldwide [1]. Substantial advances in
oral nucleoside/nucleotide analogs have been made for
treating chronic hepatitis B (CHB) in past decades.
Nucleoside or nucleotide analogues competitively inhibit
replication of HBV DNA through DNA polymerase.
Lamivudine (LAM) is a first-generation oral nucleoside
analogue for treating CHB. Previous studies in naïve
patients found a cumulative LAM resistance incidence of
70 to 80% after 4 to 5 years of therapy [2,3]. Entecavir
shows very low resistance and a potent antiviral effect in
naïve patients with CHB. Although there is no evidence of
carcinogenesis in human studies, this drug has produced
some tumors such as adenoma of the lung, neurogenic
tumors, and hepatocellular carcinoma in mice [4].
Clevudine is a nucleoside analogue of the unnatural L-
configuration, which has potent antiviral activity against
HBV [1,5]. Studies about the efficacy of initial treatment
ORIGINAL ARTICLEYang HW, et al. Initial treatment with clevudine in naive patients  373
with clevudine in naïve chronic hepatitis B patients have
been reported [1,6-11] and indicate that clevudine is very
useful for treating CHB in the short term. However, these
studies had short-term follow-ups of 12 or 24 weeks [1,6-
11]. More long-term follow-up period studies are needed
for evaluating the efficacy of clevudine treatment in
patients with CHB. We prescribed clevudine to 105 naïve
patients with CHB living in Daejeon and Chungcheong
Province in South Korea for an average of 51 weeks. 
METHODS
Study design 
This was a retrospective study and was conducted at six
medical centers in Daejeon and Chungcheong Province,
South Korea. Eligible patients were diagnosed with CHB
with or without hepatitis B e antigen (HBeAg), HBV DNA
levels above 1.0 × 10
5 copies/mL, > 2.0 × 10
4 IU/mL or >
0.4 pg/mL, and alanine aminotransferase (ALT) levels >
80 IU/L. All of the patients were prescribed clevudine for
more than 6 months. The exclusion criteria were
malignancy, alcoholism (> 20 g/day), severe fatty liver on
ultrasonography, and a medication history of nucleoside
or nucleotide analogues or interferon. The serum HBV
DNA level was measured using the DNA PCR
hybridization method (Roche, Indianapolis, IN, USA).
The lower limit of HBV DNA detection was 300
copies/mL. Viral response was defined as < 300
copies/mL of HBV DNA. We defined viral breakthrough
as a ten times rebound of HBV DNA copies compared
with previous copies during treatment. Enrolled patients
were prescribed 30 mg clevudine daily. We checked liver
biochemistry, HBeAg/Ab, and HBV DNA every 12 weeks.
Statistical analysis
SPSS version 10.2 (SPSS Inc., Chicago, IL, USA) was
used. Fisher's exact test and the chi-square test were used
to compare viral response and serum ALT normalized rate
according to HBeAg status.
Table 1. Baseline patient characteristics before
treatment
No. 105
Mean age, yr 42.7 ± 11.9 
Male / Female 65 : 40
CHB 90
LC 15 (14.3)
Follow-up period, wk 51.1 (24 - 72)
AST, IU/L 150 ± 138
ALT, IU/L 184 ± 188
HBV DNA, log copies/mL 7.1 ± 1.2
eAg positive 71
Values are presented as number (%) or mean ± SD.
CHB, chronic hepatitis B; LC, liver cirrhosis; AST,
aspartate aminotransferase; ALT, alanine aminotransf-
erase; HBV, hepatitis B virus; eAg, e antigen.
Table 2. Viral response rate of hepatitis B virus DNA and a comparison of HBeAg-positive and HBeAg-negative
patients
Total virologic response HBeAg (+) HBeAg (-) p value 
a
Initial DNA, log copies/mL 7.1 ± 1.2 7.4 ± 1.1  6.5 ± 1.0 
12 wk 25/69 (36.2) 10/43 (23.3) 15/26 (67.7) 0.004
24 wk 64/93 (68.9) 37/62 (59.7) 27/31 (87.1) 0.007
36 wk 61/73 (83.6) 38/48 (79.2) 23/25 (92.0) 0.160
48 wk 48/63 (76.2) 32/44 (72.3) 16/19 (84.2) 0.326
60 wk 25/33 (75.8) 17/26 (65.4) 8/9 (88.9) 0.179
Values are presented as number (%).
HBeAg, hepatitis B e antigen.
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RESULTS
Patient characteristics
A total of 105 patients including 15 (14.3%) patients with
liver cirrhosis were enrolled at six medical centers from
February 2007 to August 2008. Seventy-one patients
were HBeAg positive, and 34 patients were negative. The
mean age was 42.7 years, and the mean follow-up period
was 51.1 weeks. Median ALT at baseline was 184 IU/L,
and median baseline HBV DNA was 7.1 log10 copies/mL
(Table 1).
Viral response
Viral response rates in all patients were 36.2%, 68.9%,
83.6%, 76.2%, and 75.8% at 12, 24, 36, 48, and 60 weeks,
respectively. Viral response rates in HBeAg-positive
patients were 23.3%, 59.7%, 79.2%, 72.3%, and 65.4%,
and those in HBeAg-negative patients were 67.7%, 87.1%,
92.0%, 84.2%, and 88.9% at the corresponding weeks.
The rates in HBeAg-positive patients were significantly
lower at 12 and 24 weeks compared with those in HBeAg-
negative patients. No significant difference was observed
after 24 wks (Table 2).
Serum ALT normalization rate
The serum ALT normalization rates in all patients were
78.1% and 90.0% at 24 and 48 weeks, respectively. The
serum ALT normalization rates in HBeAg-positive versus
HBeAg-negative patients were 63.4% vs. 80%, 74.6% vs.
85.3%, 87.3% vs. 89.3%, and 87.7% vs. 91.3% at 12, 24, 36,
and 48 weeks, respectively (Table 3).
HBeAg loss and seroconversion rate
A total of 71e HBeAg-positive patients were enrolled.
Among these patients, the HBeAg loss was 20.3%, 30.6%,
and 43.3% at 24, 48, and 60 weeks, respectively, and the
HBeAg seroconversion rates were 13.6%, 26.5%, and
26.1%, at 24, 48, and 60 weeks (Table 4).
Table 3. Serum alanine aminotransferase (ALT) normalization rate
Weeks ALT normalization rate p value
Total HBeAg (+) HBeAg (-)
12 49/76 (64.5) 45/71 (63.4) 4/5 (80.0) NS
24 82/105 (78.1) 53/71 (74.6) 29/34 (85.3) NS
36 80/91 (87.9) 55/63 (87.3) 25/28 (89.3) NS
48 71/80 (90.0) 50/57 (87.7) 21/23 (91.3) NS
Values are presented as number (%).
HBeAg, hepatitis B e antigen; NS, not significant.
Figure 1. Incidence rate of viral breakthrough according to
treatment period. (A) Viral breakthrough rate of total patients.
(B) Viral breakthrough rate of HBeAg (+) and HBeAg (-) patients.
A
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Viral breakthrough 
The cumulative incidence rate of viral breakthrough in
the HBeAg-positive versus HBeAg-negative patients was
1.4% vs. 0%, 3.3% vs. 3.4%, and 6.7% vs. 4.1% at 24, 36,
and 48 weeks, respectively (Fig. 1). Six patients underwent
treatment for viral breakthrough. Five cases were
identified at 48 weeks, and one case at week 60. Five of
these six patients underwent a tyrosine-methionine-
aspartate-aspartate mutation (YMDD) examination, and
four patients were positive (Table 5).
DISCUSSION 
Clevudine is a nucleoside analog with an unnatural L-
configuration. The mechanism by which clevudine exerts
its antiviral effects is believed to be by the intracellular
formation of the monophosphate, diphosphate, and
triphosphate forms. Clevudine enters cells through both
facilitated nucleoside transport and nonfacilitated passive
diffusion and a substrate of three intracellular kinases is
responsible for its phosphorylation [12].
When 21 patients received 30 mg clevudine for 24
weeks and were followed up for another 24 weeks off
therapy, the clevudine treatment was well tolerated and
resulted in more potent antiviral activity and a higher ALT
normalization rate than a 12-week treatment, with
durable efficacy at week 24 of therapy [1]. However, the
experimental period in this study was less than 1 year. In
another larger-scale study, 243 patients with HBeAg-
positive CHB were randomized (3 : 1) to receive 30 mg
clevudine once daily (n = 182) or placebo (n = 61) for 24
weeks. Patients were followed for a further 24 weeks off
therapy. In that study, the 24-week clevudine therapy was
well tolerated and showed a potent and sustained antiviral
effect without evidence of viral resistance during the
treatment period [9]. Here, we administered clevudine to
105 patients with CHB for about 1 year. As in other
studies, clevudine showed powerful antiviral effects in this
study [13]. With a limit of detection of < 300 copies/mL,
the viral response rate was 76.2% (HBeAg-positive
patients, 72.3%; HBeAg-negative patients, 84.2%) at 48
weeks. This result was remarkable enough to be compared
with entecavir and tenofovir, which have negative
seroconversion rates of 67% and 76%, respectively, after a
1-year treatment, but a direct comparison is difficult
because of differences in the study methods and patient
characteristics [9,10]. 
Viral response was highest at 36 weeks and subsequ-
ently decreased because some patients experienced viral
breakthrough, and the HBV DNA PCR test at 48 or 60
weeks was not performed in some patients who had a
Table 4. HBeAg loss rate and seroconversion rate in
HBeAg-positive patients
Weeks No. of  HBeAg loss Seroconversion
patients
12 44 6 (13.6) 4 (9.1)
24 59 12 (20.3) 8 (13.6)
36 57 18 (31.6) 14 (24.6)
48 49 15 (30.6) 13 (26.5)
60 23 10 (43.3) 6 (26.1)
Values are presented as number (%).
HBeAg, hepatitis B e antigen. 
Table 5. Clinical features of patients with viral breakthrough
Age/Gender DNA at baseline, eAg at baseline ALT at baseline,  Time until VBT, YMDD 
copies/mL U/L wk mutation
31/M 5.3 × 10
8 + 262 36 Negative
50/M 7.0 × 10
6 + 78 48 Positive 
60/M 3.1 × 10
7 + 80 24 Positive
53/M 4.0 × 10
5 - 114 36 Positive
48/F 1.3 × 10
7 + 311 60 Positive
50/M 1.5 × 10
8 + 636 40 Not done
eAg, e antigen; ALT, alanine aminotransferase; VBT, viral breakthrough; YMDD, tyrosine-methionine-aspartate-aspartate
mutation.376 The Korean Journal of Internal Medicine Vol. 25, No. 4, December 2010
good viral response. 
The serum ALT normalization rate of all patients was
78.1% (HBeAg-positive patients, 74.6%; HBeAg-negative
patients, 85.3%) and 90.0% (HBeAg-positive patients,
87.7%; HBeAg-negative patients, 91.3%) at 24 and 48
weeks, respectively. This result also shows similar efficacy
to other antiviral agents. Approximately 6% of all patients
with CHB showed viral breakthrough at 48 weeks. The
viral breakthrough incidence rates were 2.9% and 7.0%
for HBeAg-negative and -positive patients respectively;
however, the difference was not statistically significant. 
The cumulative viral breakthrough rate until week 48
was 6.3% (HBeAg-positive group, 7.0% [4/57]; HBeAg-
negative group, 4.5% [1/22]) (Fig. 1).
Clevudine had powerful antiviral effects and had
relatively lower viral breakthrough incidence rate
compared with lamivudine (16-32% after 12 months); it is
expected to replace lamivudine therapy [14]. When we
performed the YMDD mutation test on five of six patients
with viral breakthrough, the YMDD mutation was found
in four patients. This suggested that clevudine cross-
reacted with lamivudine. In particular, although our
enrolled number of patients was insufficient to reach a
definitive conclusion, clevudine appears to have been
more effective for the HBeAg-negative group. Noticeably,
although this study was not controlled, the HBeAg
seroconversion rate at 48 weeks was 26.5% (13/49), which
was relatively high compared with that for lamivudine (16-
18%) [15]. A limitation of this study was that the
examinations were not performed at regular intervals at
all times, as it was a retrospective study and had a
relatively short-term follow-up period of 1 year compared
with other studies on medications that have been more
fully researched. Furthermore, although no patient
stopped clevudine because of myositis or others side
effects, we did not measure serum creatine phosphokinase
regularly or assess side effects. Despite these limitations,
the results suggest that clevudine has the potential to be
an effective therapeutic medication for patients with CHB;
however, longer-term research will be needed for further
evaluation. 
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